Fingerprint
Dive into the research topics of 'Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: Results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically